

# Cell Therapy Market Share [2020-2027]; To Soar At A CAGR Of 25.6%

*Cell Therapy Market Size to Gain a Stronghold During Forecast Period 2020 to 2027 | COVID-19 Impact Analysis*

NE WIN SIVERS DRIVE, PORTLAND, UNITED STATES, October 21, 2020 /EINPresswire.com/ -- The [cell therapy market](#) was estimated at \$7.75 Billion in 2019, and is expected to hit \$48.11 billion by 2027, registering a CAGR of 25.6% from 2020 to 2027. The Cell

Therapy Market has gained immense popularity globally due to the advent of techniques like stem cell therapy, CAR-T cell therapy, and cord blood cell therapy. Each of the therapies has gained traction owing to their extensive application in cancer and cardiovascular diseases.



Get Sample Report with Detailed COVID-19 Impact Analysis at:

<https://www.alliedmarketresearch.com/request-for-customization/5330?reqfor=covid>

Drivers, restraints, and opportunities-

Technological advancements in the medical field, rise in number of cell therapies in clinical studies, and increase in adoption of regenerative medicines fuel the growth of the market for global cell therapy. On the other hand, high costs of the therapy impede the growth to some extent. However, high growth potential in emerging markets is expected to pave the way for numerous opportunities for the key players in the sector.

Covid-19 scenario-

- Covid-19 has made biopharmaceutical reformers across the world come forward in regards to the human response to the pandemic which, in turn, has impacted the global cell therapy market positively. Also, several biotech organizations have started taking the very initiative to examine the virus's genome so that they can come up with a sustainable vaccine.

- At the same time, the use of cell therapy has become quite predominant in the development of several regenerative medicines.
- Nonetheless, during the first phase of the lockdown, most clinics across the globe stopped undertaking new cases of stem cell therapy, organ transplants, and other treatments for the next few months which, in turn, hindered the market growth to some extent.

The stem cell segment to lead the trail by 2027-

Based on cell type, the stem cell segment contributed to nearly three-fifths of the global cell therapy market share in 2019 and is expected to retain its dominance by 2027. The same segment would also grow at the fastest CAGR of 26.1% throughout the forecast period. Increase in awareness regarding storage of stem cells have a positive effect on the market. Also, the number of stem cell banks is increasing in the developing nations. These factors fuel the growth of the segment.

For Purchase Enquiry at: <https://www.alliedmarketresearch.com/purchase-enquiry/5330>

The allogeneic segment to maintain the lion's share-

Based on therapy type, the allogeneic segment accounted nearly three-fifths of the global cell therapy market revenue in 2019 and is anticipated to lead the trail from 2020 to 2027. Prevalence in cases of cancer relapse propels the segment growth. The autologous segment, on the other hand, would register the fastest CAGR of 26.0% by the end of 2027. Rise in incidences of chronic diseases such as autoimmune diseases, cancer, and blood disorders drives the segment growth.

North America to dominate in terms of revenue-

Based on region, North America generated the highest share in 2019, holding around half of the global cell therapy market. Huge amount of funding by governments and private firms for clinical trials boosts the market growth in the province. Simultaneously, Asia-Pacific would manifest the fastest CAGR of 31.6% from 2020 to 2027. Presence of large untapped opportunities such as expanding healthcare budgets and increase in disposable income of people in the region drive the market growth.

Key players in the industry-

- Osiris Therapeutics, Inc.
- Stemmedica Cell Technologies, Inc.
- JCR Pharmaceuticals Co. Ltd.
- NuVasive, Inc.
- Cells for cells
- Colongene Tissue Gene, Inc.

- Medipost Co., Ltd.
- BiolostemTerapieAvanzateS.r.l.
- Mesoblast Ltd.

## Table Of Content

### CHAPTER 1:INTRODUCTION

- 1.1.Report description
- 1.2.Key benefits for stakeholders
- 1.3.Key market segments
- 1.4.Research methodology
  - 1.4.1.Secondary research
  - 1.4.2.Primary research
  - 1.4.3.Analyst tools & models

### CHAPTER 2:EXECUTIVE SUMMARY

- 2.1.Key findings of the study
- 2.2.CXO perspective

### CHAPTER 3:MARKET OVERVIEW

- 3.1.Market definition and scope
- 3.2.Key findings
  - 3.2.1.Top player positioning
  - 3.2.2.Top investment pockets
  - 3.2.3.Top winning strategies
- 3.3.Porter's five forces analysis
- 3.4.Impact Analysis
  - 3.4.1.Drivers
    - 3.4.1.1.Technological advancements in the field of cell therapy
    - 3.4.1.2.Rise in number of cell therapy clinical studies
    - 3.4.1.3.Rise in adoption of regenerative medicine
  - 3.4.2.Restrictant

3.4.2.1.Developing stage and pricing

3.4.3.Opportunity

3.4.3.1.High growth potential in emerging markets

3.5.Impact of COVID-19 on cell therapy market

## CHAPTER 4:CELL THERAPY MARKET, BY CELL TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Stem cell

4.2.1.Key market trends and opportunities

4.2.2.Market size and forecast, by region

4.2.3.Market size and forecast, by type

4.2.3.1.Bone marrow, market size and forecast

4.2.3.2.Blood, market size and forecast

4.2.3.3.Umbilical cord-derived, market size and forecast

4.2.3.4.Adipose-derived stem cell, market size and forecast

4.2.3.5.Others (placenta, and nonspecific cells), market size and forecast

4.3.Non-stem cell

4.3.1.Key market trends and opportunities

4.3.2.Market size and forecast, by region

## CHAPTER 5:CELL THERAPY MARKET, BY THERAPY TYPE

5.1.Overview

5.1.1.Market size and forecast

5.2.Autologous

5.2.1.Key market trends and opportunities

5.2.2.Market size and forecast, by region

5.2.3.Market analysis, by country

## 5.3.Allogeneic

### 5.3.1.Key market trends and opportunities

### 5.3.2.Market size and forecast, by region

### 5.3.3.Market analysis, by country

## CHAPTER 6:CELL THERAPY MARKET, BY THERAPEUTIC AREA

### 6.1.Overview

#### 6.1.1.Market size and forecast

### 6.2.Malignancies

#### 6.2.1.Market size and forecast, by region

#### 6.2.2.Market analysis, by country

### 6.3.Musculoskeletal disorders

#### 6.3.1.Market size and forecast, by region

#### 6.3.2.Market analysis, by country

### 6.4.Autoimmune disorders

#### 6.4.1.Market size and forecast, by region

#### 6.4.2.Market analysis, by country

### 6.5.Dermatology

#### 6.5.1.Market size and forecast, by region

#### 6.5.2.Market analysis, by country

### 6.6.Others

#### 6.6.1.Market size and forecast, by region

#### 6.6.2.Market analysis, by country

## CHAPTER 7:CELL THERAPY MARKET, BY END USER

### 7.1.Overview

#### 7.1.1.Market size and forecast

## 7.2.Hospitals & clinics

7.2.1.Key market trends and opportunities

7.2.2.Market size and forecast, by region

7.2.3.Market analysis, by country

## 7.3.Academic & Research Institutes

7.3.1.Key market trends and opportunities

7.3.2.Market size and forecast, by region

7.3.3.Market analysis, by country...

David Correa

Allied Analytics LLP

+1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/528912289>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.